department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

lenvatinib · pharmadog

pharmadog
drugs
lenvatinib

drug

patient view →

lenvatinib

updated 2mo ago

by Cancer Institute and Hospital Chinese Academy of Medical Sciences

community read0 votes

all catalysts(1)

phase 2 completion · 1

phase 2 completion

Cancer Institute and Hospital Chinese Academy of Medical Sciences — lenvatinib (Phase II Trial Completion)

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 32m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

tagOncology20 co-mentions · 3 sources
companyEisai Co Ltd2 co-mentions · 2 sources
tagInfectious Disease2 co-mentions · 2 sources
tagBreast Cancer2 co-mentions · 2 sources
tagColorectal Cancer2 co-mentions · 2 sources
tagMelanoma2 co-mentions · 2 sources
druglenvatinib mesylate2 co-mentions · 2 sources
companyCancer Institute and Hospital Chinese Academy of Medical Sciences1 co-mentions · 1 sources

Trials studying lenvatinib

phase2A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)recruitingn=230
phase2A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)completedn=245
phase3Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)recruitingn=3,500
phase2A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancerrecruitingn=54
phase3Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)recruitingn=450
phase2Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)active not recruitingn=370
phase3A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)active not recruitingn=747
phase3Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)completedn=895

more trials →